| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| GILD - Guild Esports Plc | BUY | 1,403 @ USD 140.97 | USD 197,781 | The ETF bought 1403 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 140.97 compared to the previous average buy price of 118.132. This is 19.3% higher than average price of previous purchases of GILD. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 407 @ USD 474.17 | USD 192,987 | The ETF bought 407 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 474.17 compared to the previous average buy price of 429.595. This is 10.4% higher than average price of previous purchases of VRTX. |
| AMGN - Amgen Inc | BUY | 511 @ USD 351.32 | USD 179,525 | The ETF bought 511 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 351.32 compared to the previous average buy price of 303.818. This is 15.6% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 168 @ USD 771.25 | USD 129,570 | The ETF bought 168 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 771.25 compared to the previous average buy price of 659.146. This is 17.0% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 215 @ USD 354.75 | USD 76,271 | The ETF bought 215 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 354.75 compared to the previous average buy price of 392.202. This is -9.5% lower than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 346 @ USD 162.64 | USD 56,273 | The ETF bought 346 new shares of INSM (Insmed Inc). The shares were bought for an average price of 162.64 compared to the previous average buy price of 144.368. This is 12.7% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 238 @ USD 174.12 | USD 41,441 | The ETF bought 238 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 174.12 compared to the previous average buy price of 151.828. This is 14.7% higher than average price of previous purchases of BIIB. |
| ARGX - argenx NV ADR | BUY | 47 @ USD 864.42 | USD 40,628 | The ETF bought 47 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 864.42 compared to the previous average buy price of 727.046. This is 18.9% higher than average price of previous purchases of ARGX. |
| ILMN - Illumina Inc | BUY | 248 @ USD 152.09 | USD 37,718 | The ETF bought 248 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 152.09 compared to the previous average buy price of 110.492. This is 37.6% higher than average price of previous purchases of ILMN. |
| UTHR - United Therapeutics Corporation | BUY | 70 @ USD 476.78 | USD 33,375 | The ETF bought 70 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 476.78 compared to the previous average buy price of 391.679. This is 21.7% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 319 @ USD 103.47 | USD 33,007 | The ETF bought 319 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 103.47 compared to the previous average buy price of 84.7174. This is 22.1% higher than average price of previous purchases of INCY. |
| RVMD - Revolution Medicines Inc | BUY | 314 @ USD 99.82 | USD 31,343 | The ETF bought 314 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 99.82 compared to the previous average buy price of 58.288. This is 71.3% higher than average price of previous purchases of RVMD. |
| MRNA - Moderna Inc | BUY | 634 @ USD 45.45 | USD 28,815 | The ETF bought 634 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 45.45 compared to the previous average buy price of 29.736. This is 52.8% higher than average price of previous purchases of MRNA. |
| RPRX - Royalty Pharma Plc | BUY | 694 @ USD 40.74 | USD 28,274 | The ETF bought 694 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 40.74 compared to the previous average buy price of 37.1363. This is 9.7% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 46 @ USD 602.25 | USD 27,704 | The ETF bought 46 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 602.25 compared to the previous average buy price of 466.887. This is 29.0% higher than average price of previous purchases of MEDP. |
| ROIV - Roivant Sciences Ltd | BUY | 1,129 @ USD 22.53 | USD 25,436 | The ETF bought 1129 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 22.53 compared to the previous average buy price of 16.2817. This is 38.4% higher than average price of previous purchases of ROIV. |
| VTRS - Viatris Inc | BUY | 1,870 @ USD 13.12 | USD 24,534 | The ETF bought 1870 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 13.12 compared to the previous average buy price of 10.3053. This is 27.3% higher than average price of previous purchases of VTRS. |
| BBIO - BridgeBio Pharma Inc | BUY | 313 @ USD 77.87 | USD 24,373 | The ETF bought 313 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 77.87 compared to the previous average buy price of 55.3363. This is 40.7% higher than average price of previous purchases of BBIO. |
| GH - Guardant Health Inc | BUY | 210 @ USD 114.59 | USD 24,064 | The ETF bought 210 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 114.59 compared to the previous average buy price of 74.3835. This is 54.1% higher than average price of previous purchases of GH. |
| ASND - Ascendis Pharma AS | BUY | 100 @ USD 238.8 | USD 23,880 | The ETF bought 100 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 238.8 compared to the previous average buy price of 189.455. This is 26.0% higher than average price of previous purchases of ASND. |
| NBIX - Neurocrine Biosciences Inc | BUY | 162 @ USD 133.89 | USD 21,690 | The ETF bought 162 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 133.89 compared to the previous average buy price of 135.526. This is -1.2% lower than average price of previous purchases of NBIX. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 263 @ USD 82.14 | USD 21,603 | The ETF bought 263 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 82.14 compared to the previous average buy price of 59.6643. This is 37.7% higher than average price of previous purchases of IONS. |
| SNY - Sanofi ADR | BUY | 430 @ USD 47.49 | USD 20,421 | The ETF bought 430 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 47.49 compared to the previous average buy price of 49.5092. This is -4.1% lower than average price of previous purchases of SNY. |
| BNTX - BioNTech SE | BUY | 164 @ USD 119.34 | USD 19,572 | The ETF bought 164 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 119.34 compared to the previous average buy price of 103.605. This is 15.2% higher than average price of previous purchases of BNTX. |
| SMMT - Summit Therapeutics PLC | BUY | 1,209 @ USD 15.9 | USD 19,223 | The ETF bought 1209 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 15.9 compared to the previous average buy price of 20.082. This is -20.8% lower than average price of previous purchases of SMMT. |
| EXEL - Exelixis Inc | BUY | 435 @ USD 43.74 | USD 19,027 | The ETF bought 435 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 43.74 compared to the previous average buy price of 42.033. This is 4.1% higher than average price of previous purchases of EXEL. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 37 @ USD 500.39 | USD 18,514 | The ETF bought 37 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 500.39 compared to the previous average buy price of 424.172. This is 18.0% higher than average price of previous purchases of MDGL. |
| RNA - Avidity Biosciences Inc | BUY | 245 @ USD 72.64 | USD 17,797 | The ETF bought 245 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.64 compared to the previous average buy price of 53.4082. This is 36.0% higher than average price of previous purchases of RNA. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 312 @ USD 56.85 | USD 17,737 | The ETF bought 312 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 56.85 compared to the previous average buy price of 56.9606. This is -0.2% lower than average price of previous purchases of BMRN. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 99 @ USD 167.85 | USD 16,617 | The ETF bought 99 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 167.85 compared to the previous average buy price of 139.64. This is 20.2% higher than average price of previous purchases of JAZZ. |
| AXSM - Axsome Therapeutics Inc | BUY | 82 @ USD 188.02 | USD 15,418 | The ETF bought 82 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 188.02 compared to the previous average buy price of 130.444. This is 44.1% higher than average price of previous purchases of AXSM. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 221 @ USD 66.91 | USD 14,787 | The ETF bought 221 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 66.91 compared to the previous average buy price of 34.2879. This is 95.1% higher than average price of previous purchases of ARWR. |
| HALO - Halozyme Therapeutics Inc | BUY | 191 @ USD 70.22 | USD 13,412 | The ETF bought 191 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 70.22 compared to the previous average buy price of 62.8333. This is 11.8% higher than average price of previous purchases of HALO. |
| KRYS - Krystal Biotech Inc | BUY | 47 @ USD 277.36 | USD 13,036 | The ETF bought 47 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 277.36 compared to the previous average buy price of 190.657. This is 45.5% higher than average price of previous purchases of KRYS. |
| PRAX - Praxis Precision Medicines Inc | BUY | 41 @ USD 314.75 | USD 12,905 | The ETF bought 41 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 314.75 compared to the previous average buy price of 147.559. This is 113.3% higher than average price of previous purchases of PRAX. |
| CYTK - Cytokinetics Inc | BUY | 199 @ USD 64.01 | USD 12,738 | The ETF bought 199 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 64.01 compared to the previous average buy price of 50.822. This is 25.9% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 117 @ USD 106.45 | USD 12,455 | The ETF bought 117 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 106.45 compared to the previous average buy price of 90.995. This is 17.0% higher than average price of previous purchases of NUVL. |
| PCVX - Vaxcyte Inc | BUY | 213 @ USD 54.35 | USD 11,577 | The ETF bought 213 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 54.35 compared to the previous average buy price of 45.288. This is 20.0% higher than average price of previous purchases of PCVX. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 108 @ USD 105.53 | USD 11,397 | The ETF bought 108 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 105.53 compared to the previous average buy price of 86.2743. This is 22.3% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 130 @ USD 75.49 | USD 9,814 | The ETF bought 130 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 75.49 compared to the previous average buy price of 62.9545. This is 19.9% higher than average price of previous purchases of PTCT. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 108 @ USD 89.51 | USD 9,667 | The ETF bought 108 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 89.51 compared to the previous average buy price of 37.8274. This is 136.6% higher than average price of previous purchases of GPCR. |
| COGT - Cogent Biosciences Inc | BUY | 249 @ USD 38.51 | USD 9,589 | The ETF bought 249 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 38.51 compared to the previous average buy price of 21.0833. This is 82.7% higher than average price of previous purchases of COGT. |
| IBRX - Immunitybio Inc | BUY | 1,599 @ USD 5.95 | USD 9,514 | The ETF bought 1599 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 5.95 compared to the previous average buy price of 2.86729. This is 107.5% higher than average price of previous purchases of IBRX. |
| ALKS - Alkermes Plc | BUY | 268 @ USD 33.52 | USD 8,983 | The ETF bought 268 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 33.52 compared to the previous average buy price of 30.1876. This is 11.0% higher than average price of previous purchases of ALKS. |
| PTGX - Protagonist Therapeutics Inc | BUY | 102 @ USD 83.08 | USD 8,474 | The ETF bought 102 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 83.08 compared to the previous average buy price of 67.1084. This is 23.8% higher than average price of previous purchases of PTGX. |
| KYMR - Kymera Therapeutics Inc | BUY | 117 @ USD 72.15 | USD 8,442 | The ETF bought 117 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 72.15 compared to the previous average buy price of 54.9949. This is 31.2% higher than average price of previous purchases of KYMR. |
| CRSP - Crispr Therapeutics AG | BUY | 155 @ USD 54.26 | USD 8,410 | The ETF bought 155 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 54.26 compared to the previous average buy price of 53.4633. This is 1.5% higher than average price of previous purchases of CRSP. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 83 @ USD 99.27 | USD 8,239 | The ETF bought 83 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 99.27 compared to the previous average buy price of 63.3492. This is 56.7% higher than average price of previous purchases of MIRM. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 154 @ USD 52.965 | USD 8,157 | The ETF bought 154 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 52.965 compared to the previous average buy price of 40.0424. This is 32.3% higher than average price of previous purchases of CRNX. |
| IMVT - Immunovant Inc | BUY | 285 @ USD 26.83 | USD 7,647 | The ETF bought 285 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 26.83 compared to the previous average buy price of 20.0047. This is 34.1% higher than average price of previous purchases of IMVT. |
| SRRK - Scholar Rock Holding Corp | BUY | 166 @ USD 43.99 | USD 7,302 | The ETF bought 166 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 43.99 compared to the previous average buy price of 37.8075. This is 16.4% higher than average price of previous purchases of SRRK. |
| CGON - CG Oncology, Inc. Common stock | BUY | 131 @ USD 55.1 | USD 7,218 | The ETF bought 131 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 55.1 compared to the previous average buy price of 35.7023. This is 54.3% higher than average price of previous purchases of CGON. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 275 @ USD 26.2 | USD 7,205 | The ETF bought 275 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.2 compared to the previous average buy price of 22.6644. This is 15.6% higher than average price of previous purchases of ACAD. |
| FOLD - Amicus Therapeutics Inc | BUY | 501 @ USD 14.29 | USD 7,159 | The ETF bought 501 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.29 compared to the previous average buy price of 8.87341. This is 61.0% higher than average price of previous purchases of FOLD. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 510 @ USD 13.83 | USD 7,053 | The ETF bought 510 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 13.83 compared to the previous average buy price of 10.1192. This is 36.7% higher than average price of previous purchases of AMRX. |
| GRAL - GRAIL, LLC | BUY | 63 @ USD 108.98 | USD 6,866 | The ETF bought 63 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 108.98 compared to the previous average buy price of 68.8411. This is 58.3% higher than average price of previous purchases of GRAL. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 89 @ USD 72.38 | USD 6,442 | The ETF bought 89 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 72.38 compared to the previous average buy price of 59.2577. This is 22.1% higher than average price of previous purchases of APGE. |
| ACLX - Arcellx Inc | BUY | 94 @ USD 68.51 | USD 6,440 | The ETF bought 94 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 68.51 compared to the previous average buy price of 71.6385. This is -4.4% lower than average price of previous purchases of ACLX. |
| ADMA - ADMA Biologics Inc | BUY | 386 @ USD 16.58 | USD 6,400 | The ETF bought 386 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 16.58 compared to the previous average buy price of 17.7958. This is -6.8% lower than average price of previous purchases of ADMA. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 32 @ USD 195.49 | USD 6,256 | The ETF bought 32 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 195.49 compared to the previous average buy price of 155.293. This is 25.9% higher than average price of previous purchases of LGND. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 125 @ USD 42.39 | USD 5,299 | The ETF bought 125 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 42.39 compared to the previous average buy price of 38.0167. This is 11.5% higher than average price of previous purchases of XENE. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 199 @ USD 26.33 | USD 5,240 | The ETF bought 199 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 26.33 compared to the previous average buy price of 20.9937. This is 25.4% higher than average price of previous purchases of ARQT. |
| TERN - Tern Plc | BUY | 146 @ USD 35.09 | USD 5,123 | The ETF bought 146 new shares of TERN (Tern Plc). The shares were bought for an average price of 35.09 compared to the previous average buy price of 14.4034. This is 143.6% higher than average price of previous purchases of TERN. |
| VCYT - Veracyte Inc | BUY | 128 @ USD 39.8 | USD 5,094 | The ETF bought 128 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 39.8 compared to the previous average buy price of 35.8777. This is 10.9% higher than average price of previous purchases of VCYT. |
| BEAM - Beam Therapeutics Inc | BUY | 165 @ USD 30.7 | USD 5,066 | The ETF bought 165 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 30.7 compared to the previous average buy price of 22.9857. This is 33.6% higher than average price of previous purchases of BEAM. |
| DNLI - Denali Therapeutics Inc | BUY | 238 @ USD 21.25 | USD 5,058 | The ETF bought 238 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 21.25 compared to the previous average buy price of 16.398. This is 29.6% higher than average price of previous purchases of DNLI. |
| EWTX - Edgewise Therapeutics Inc | BUY | 172 @ USD 29.36 | USD 5,050 | The ETF bought 172 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 29.36 compared to the previous average buy price of 18.9952. This is 54.6% higher than average price of previous purchases of EWTX. |
| IRON - Ironveld Plc | BUY | 61 @ USD 82.14 | USD 5,011 | The ETF bought 61 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 82.14 compared to the previous average buy price of 67.1842. This is 22.3% higher than average price of previous purchases of IRON. |
| IDYA - Ideaya Biosciences Inc | BUY | 142 @ USD 34.74 | USD 4,933 | The ETF bought 142 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 34.74 compared to the previous average buy price of 27.5061. This is 26.3% higher than average price of previous purchases of IDYA. |
| VERA - Vera Therapeutics Inc | BUY | 104 @ USD 46.75 | USD 4,862 | The ETF bought 104 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 46.75 compared to the previous average buy price of 32.3074. This is 44.7% higher than average price of previous purchases of VERA. |
| ERAS - Erasca Inc | BUY | 461 @ USD 10.5 | USD 4,841 | The ETF bought 461 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 10.5 compared to the previous average buy price of 2.84876. This is 268.6% higher than average price of previous purchases of ERAS. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 248 @ USD 19.23 | USD 4,769 | The ETF bought 248 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 19.23 compared to the previous average buy price of 13.9548. This is 37.8% higher than average price of previous purchases of ADPT. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 69 @ USD 68.15 | USD 4,702 | The ETF bought 69 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 68.15 compared to the previous average buy price of 58.7245. This is 16.1% higher than average price of previous purchases of TARS. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 93 @ USD 49.44 | USD 4,598 | The ETF bought 93 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 49.44 compared to the previous average buy price of 40.8593. This is 21.0% higher than average price of previous purchases of SUPN. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 205 @ USD 21.81 | USD 4,471 | The ETF bought 205 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 21.81 compared to the previous average buy price of 21.1784. This is 3.0% higher than average price of previous purchases of APLS. |
| TVTX - Travere Therapeutics Inc | BUY | 145 @ USD 30.03 | USD 4,354 | The ETF bought 145 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 30.03 compared to the previous average buy price of 24.9176. This is 20.5% higher than average price of previous purchases of TVTX. |
| TWST - Twist Bioscience Corp | BUY | 99 @ USD 42.6 | USD 4,217 | The ETF bought 99 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 42.6 compared to the previous average buy price of 35.3224. This is 20.6% higher than average price of previous purchases of TWST. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 128 @ USD 32.84 | USD 4,204 | The ETF bought 128 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 32.84 compared to the previous average buy price of 26.9392. This is 21.9% higher than average price of previous purchases of MLYS. |
| SYRE - Spyre Therapeutics Inc. | BUY | 126 @ USD 33.36 | USD 4,203 | The ETF bought 126 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 33.36 compared to the previous average buy price of 25.5106. This is 30.8% higher than average price of previous purchases of SYRE. |
| DYN - Dyne Therapeutics Inc | BUY | 232 @ USD 18.04 | USD 4,185 | The ETF bought 232 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 18.04 compared to the previous average buy price of 14.7558. This is 22.3% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 232 @ USD 18.04 | USD 4,185 | The ETF bought 232 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 18.04 compared to the previous average buy price of 14.7558. This is 22.3% higher than average price of previous purchases of DYN. |
| TXG - 10X Genomics Inc | BUY | 189 @ USD 21.62 | USD 4,086 | The ETF bought 189 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 21.62 compared to the previous average buy price of 14.5282. This is 48.8% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 189 @ USD 21.62 | USD 4,086 | The ETF bought 189 new shares of TXG (Terex Corporation). The shares were bought for an average price of 21.62 compared to the previous average buy price of 14.5282. This is 48.8% higher than average price of previous purchases of TXG. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 157 @ USD 25.99 | USD 4,080 | The ETF bought 157 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 25.99 compared to the previous average buy price of 19.8752. This is 30.8% higher than average price of previous purchases of CNTA. |
| RARE - Ultragenyx | BUY | 157 @ USD 24.62 | USD 3,865 | The ETF bought 157 new shares of RARE (Ultragenyx). The shares were bought for an average price of 24.62 compared to the previous average buy price of 34.1879. This is -28.0% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 157 @ USD 24.62 | USD 3,865 | The ETF bought 157 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 24.62 compared to the previous average buy price of 34.1879. This is -28.0% lower than average price of previous purchases of RARE. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 835 @ USD 4.6 | USD 3,841 | The ETF bought 835 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.6 compared to the previous average buy price of 5.24778. This is -12.3% lower than average price of previous purchases of RXRX. |
| SRPT - Sarepta Therapeutics Inc | BUY | 170 @ USD 22.17 | USD 3,769 | The ETF bought 170 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 22.17 compared to the previous average buy price of 29.1667. This is -24.0% lower than average price of previous purchases of SRPT. |
| OCUL - Ocular Therapeutix Inc | BUY | 346 @ USD 10.85 | USD 3,754 | The ETF bought 346 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 10.85 compared to the previous average buy price of 11.1115. This is -2.4% lower than average price of previous purchases of OCUL. |
| WVE - Wave Life Sciences Ltd | BUY | 271 @ USD 13.36 | USD 3,621 | The ETF bought 271 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 13.36 compared to the previous average buy price of 9.02138. This is 48.1% higher than average price of previous purchases of WVE. |
| HRMY - Harmony Biosciences Holdings | BUY | 94 @ USD 37.68 | USD 3,542 | The ETF bought 94 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 37.68 compared to the previous average buy price of 33.8653. This is 11.3% higher than average price of previous purchases of HRMY. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 128 @ USD 26.1 | USD 3,341 | The ETF bought 128 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 26.1 compared to the previous average buy price of 14.2972. This is 82.6% higher than average price of previous purchases of OLMA. |
| GMAB - Genmab AS | BUY | 95 @ USD 34.4 | USD 3,268 | The ETF bought 95 new shares of GMAB (Genmab AS). The shares were bought for an average price of 34.4 compared to the previous average buy price of 28.7074. This is 19.8% higher than average price of previous purchases of GMAB. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 73 @ USD 44.64 | USD 3,259 | The ETF bought 73 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 44.64 compared to the previous average buy price of 33.8403. This is 31.9% higher than average price of previous purchases of KNSA. |
| NRIX - Nurix Therapeutics Inc | BUY | 165 @ USD 19.41 | USD 3,203 | The ETF bought 165 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 19.41 compared to the previous average buy price of 15.1507. This is 28.1% higher than average price of previous purchases of NRIX. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 214 @ USD 14.57 | USD 3,118 | The ETF bought 214 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 14.57 compared to the previous average buy price of 11.8239. This is 23.2% higher than average price of previous purchases of AUPH. |
| ARDX - Ardelyx Inc | BUY | 395 @ USD 7.89 | USD 3,117 | The ETF bought 395 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 7.89 compared to the previous average buy price of 5.18766. This is 52.1% higher than average price of previous purchases of ARDX. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 141 @ USD 21.31 | USD 3,005 | The ETF bought 141 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 21.31 compared to the previous average buy price of 14.896. This is 43.1% higher than average price of previous purchases of SNDX. |
| VCEL - Vericel Corp Ord | BUY | 82 @ USD 36.58 | USD 3,000 | The ETF bought 82 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 36.58 compared to the previous average buy price of 39.6344. This is -7.7% lower than average price of previous purchases of VCEL. |
| DVAX - Dynavax Technologies Corporation | BUY | 191 @ USD 15.48 | USD 2,957 | The ETF bought 191 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.48 compared to the previous average buy price of 11.3912. This is 35.9% higher than average price of previous purchases of DVAX. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 36 @ USD 80.45 | USD 2,896 | The ETF bought 36 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 80.45 compared to the previous average buy price of 75.9231. This is 6.0% higher than average price of previous purchases of ANIP. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 122 @ USD 23.25 | USD 2,837 | The ETF bought 122 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 23.25 compared to the previous average buy price of 18.2265. This is 27.6% higher than average price of previous purchases of ZYME. |
| PHVS - Pharvaris BV | BUY | 104 @ USD 27.19 | USD 2,828 | The ETF bought 104 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 27.19 compared to the previous average buy price of 25.6022. This is 6.2% higher than average price of previous purchases of PHVS. |
| MNKD - MannKind Corp | BUY | 499 @ USD 5.59 | USD 2,789 | The ETF bought 499 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.59 compared to the previous average buy price of 5.00763. This is 11.6% higher than average price of previous purchases of MNKD. |
| NTLA - Intellia Therapeutics Inc | BUY | 188 @ USD 14.83 | USD 2,788 | The ETF bought 188 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 14.83 compared to the previous average buy price of 11.5903. This is 28.0% higher than average price of previous purchases of NTLA. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 178 @ USD 15.47 | USD 2,754 | The ETF bought 178 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 15.47 compared to the previous average buy price of 9.63015. This is 60.6% higher than average price of previous purchases of AMLX. |
| STOK - Stoke Therapeutics Inc | BUY | 93 @ USD 29.51 | USD 2,744 | The ETF bought 93 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 29.51 compared to the previous average buy price of 21.051. This is 40.2% higher than average price of previous purchases of STOK. |
| AGIO - Agios Pharm | BUY | 95 @ USD 28.67 | USD 2,724 | The ETF bought 95 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 28.67 compared to the previous average buy price of 33.1626. This is -13.5% lower than average price of previous purchases of AGIO. |
| PGEN - Precigen Inc | BUY | 574 @ USD 4.73 | USD 2,715 | The ETF bought 574 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.73 compared to the previous average buy price of 3.16268. This is 49.6% higher than average price of previous purchases of PGEN. |
| RAPT - RAPT Therapeutics Inc | BUY | 46 @ USD 57.61 | USD 2,650 | The ETF bought 46 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 57.61 compared to the previous average buy price of 36.1427. This is 59.4% higher than average price of previous purchases of RAPT. |
| NVAX - Novavax Inc | BUY | 265 @ USD 9.82 | USD 2,602 | The ETF bought 265 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 9.82 compared to the previous average buy price of 7.31317. This is 34.3% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 265 @ USD 9.82 | USD 2,602 | The ETF bought 265 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 9.82 compared to the previous average buy price of 7.31317. This is 34.3% higher than average price of previous purchases of NVAX. |
| TNGX - Tango Therapeutics Inc | BUY | 219 @ USD 11.85 | USD 2,595 | The ETF bought 219 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 11.85 compared to the previous average buy price of 8.24166. This is 43.8% higher than average price of previous purchases of TNGX. |
| HROW - Harrow Health Inc | BUY | 60 @ USD 42.98 | USD 2,579 | The ETF bought 60 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 42.98 compared to the previous average buy price of 38.441. This is 11.8% higher than average price of previous purchases of HROW. |
| FTRE - Fortrea Holdings Inc. | BUY | 150 @ USD 17.12 | USD 2,568 | The ETF bought 150 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 17.12 compared to the previous average buy price of 9.60541. This is 78.2% higher than average price of previous purchases of FTRE. |
| ELVN - Enliven Therapeutics Inc. | BUY | 96 @ USD 26.16 | USD 2,511 | The ETF bought 96 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 26.16 compared to the previous average buy price of 21.2161. This is 23.3% higher than average price of previous purchases of ELVN. |
| LEGN - Legend Biotech Corp | BUY | 137 @ USD 18.27 | USD 2,503 | The ETF bought 137 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 18.27 compared to the previous average buy price of 31.2852. This is -41.6% lower than average price of previous purchases of LEGN. |
| IMCR - Immunocore Holdings Ltd | BUY | 71 @ USD 35.05 | USD 2,489 | The ETF bought 71 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 35.05 compared to the previous average buy price of 34.1775. This is 2.6% higher than average price of previous purchases of IMCR. |
| QURE - Uniqure NV | BUY | 102 @ USD 24.37 | USD 2,486 | The ETF bought 102 new shares of QURE (Uniqure NV). The shares were bought for an average price of 24.37 compared to the previous average buy price of 23.4547. This is 3.9% higher than average price of previous purchases of QURE. |
| INVA - Innoviva Inc | BUY | 122 @ USD 19.72 | USD 2,406 | The ETF bought 122 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.72 compared to the previous average buy price of 19.6382. This is 0.4% higher than average price of previous purchases of INVA. |
| RLAY - Relay Therapeutics Inc | BUY | 283 @ USD 8.5 | USD 2,406 | The ETF bought 283 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.5 compared to the previous average buy price of 5.22404. This is 62.7% higher than average price of previous purchases of RLAY. |
| NVCR - Novocure Ltd | BUY | 182 @ USD 13.05 | USD 2,375 | The ETF bought 182 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 13.05 compared to the previous average buy price of 15.176. This is -14.0% lower than average price of previous purchases of NVCR. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 343 @ USD 6.76 | USD 2,319 | The ETF bought 343 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 6.76 compared to the previous average buy price of 7.89046. This is -14.3% lower than average price of previous purchases of BCRX. |
| COLL - Collegium Pharmaceutical Inc | BUY | 51 @ USD 45.32 | USD 2,311 | The ETF bought 51 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 45.32 compared to the previous average buy price of 37.0562. This is 22.3% higher than average price of previous purchases of COLL. |
| ANAB - AnaptysBio Inc | BUY | 45 @ USD 49.73 | USD 2,238 | The ETF bought 45 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 49.73 compared to the previous average buy price of 30.9416. This is 60.7% higher than average price of previous purchases of ANAB. |
| SANA - Sana Biotechnology Inc | BUY | 434 @ USD 4.97 | USD 2,157 | The ETF bought 434 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.97 compared to the previous average buy price of 3.64101. This is 36.5% higher than average price of previous purchases of SANA. |
| TSHA - Taysha Gene Therapies Inc | BUY | 447 @ USD 4.76 | USD 2,128 | The ETF bought 447 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.76 compared to the previous average buy price of 3.44872. This is 38.0% higher than average price of previous purchases of TSHA. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 167 @ USD 12.33 | USD 2,059 | The ETF bought 167 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 12.33 compared to the previous average buy price of 8.1165. This is 51.9% higher than average price of previous purchases of DAWN. |
| CSTL - Castle Biosciences Inc | BUY | 48 @ USD 42.84 | USD 2,056 | The ETF bought 48 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 42.84 compared to the previous average buy price of 28.4546. This is 50.6% higher than average price of previous purchases of CSTL. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 272 @ USD 7.51 | USD 2,043 | The ETF bought 272 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.51 compared to the previous average buy price of 6.39817. This is 17.4% higher than average price of previous purchases of XERS. |
| AMPH - Amphastar P | BUY | 75 @ USD 26.25 | USD 1,969 | The ETF bought 75 new shares of AMPH (Amphastar P). The shares were bought for an average price of 26.25 compared to the previous average buy price of 25.9342. This is 1.2% higher than average price of previous purchases of AMPH. |
| SVRA - Savara Inc | BUY | 334 @ USD 5.85 | USD 1,954 | The ETF bought 334 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.85 compared to the previous average buy price of 4.47614. This is 30.7% higher than average price of previous purchases of SVRA. |
| ABCL - Abcellera Biologics Inc | BUY | 487 @ USD 3.99 | USD 1,943 | The ETF bought 487 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.99 compared to the previous average buy price of 3.8844. This is 2.7% higher than average price of previous purchases of ABCL. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 645 @ USD 2.98 | USD 1,922 | The ETF bought 645 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.98 compared to the previous average buy price of 2.39552. This is 24.4% higher than average price of previous purchases of IOVA. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 158 @ USD 12.11 | USD 1,913 | The ETF bought 158 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 12.11 compared to the previous average buy price of 10.7562. This is 12.6% higher than average price of previous purchases of ORIC. |
| GRFS - Grifols SA ADR | BUY | 201 @ USD 9.29 | USD 1,867 | The ETF bought 201 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.29 compared to the previous average buy price of 9.17901. This is 1.2% higher than average price of previous purchases of GRFS. |
| VIR - Vir Biotechnology Inc | BUY | 227 @ USD 7.69 | USD 1,746 | The ETF bought 227 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 7.69 compared to the previous average buy price of 5.96891. This is 28.8% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 227 @ USD 7.69 | USD 1,746 | The ETF bought 227 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 7.69 compared to the previous average buy price of 5.96891. This is 28.8% higher than average price of previous purchases of VIR. |
| SPRY - Silverback Therapeutics Inc | BUY | 163 @ USD 10.54 | USD 1,718 | The ETF bought 163 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 10.54 compared to the previous average buy price of 12.2168. This is -13.7% lower than average price of previous purchases of SPRY. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 118 @ USD 14.23 | USD 1,679 | The ETF bought 118 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.23 compared to the previous average buy price of 11.1763. This is 27.3% higher than average price of previous purchases of PHAT. |
| VTYX - Ventyx Biosciences Inc | BUY | 119 @ USD 13.99 | USD 1,665 | The ETF bought 119 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 13.99 compared to the previous average buy price of 13.6556. This is 2.4% higher than average price of previous purchases of VTYX. |
| TBPH - Theravance Biopharma Inc | BUY | 83 @ USD 19.82 | USD 1,645 | The ETF bought 83 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 19.82 compared to the previous average buy price of 14.5701. This is 36.0% higher than average price of previous purchases of TBPH. |
| URGN - UroGen Pharma Ltd | BUY | 73 @ USD 21.85 | USD 1,595 | The ETF bought 73 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 21.85 compared to the previous average buy price of 17.2378. This is 26.8% higher than average price of previous purchases of URGN. |
| XNCR - Xencor Inc | BUY | 118 @ USD 13.17 | USD 1,554 | The ETF bought 118 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 13.17 compared to the previous average buy price of 12.6313. This is 4.3% higher than average price of previous purchases of XNCR. |
| JANX - Janux Therapeutics Inc | BUY | 99 @ USD 14.73 | USD 1,458 | The ETF bought 99 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 14.73 compared to the previous average buy price of 24.2575. This is -39.3% lower than average price of previous purchases of JANX. |
| GERN - Geron Corporation | BUY | 1,049 @ USD 1.38 | USD 1,448 | The ETF bought 1049 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.38 compared to the previous average buy price of 1.41837. This is -2.7% lower than average price of previous purchases of GERN. |
| PCRX - Pacira BioSciences, Inc. | BUY | 72 @ USD 19.85 | USD 1,429 | The ETF bought 72 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 19.85 compared to the previous average buy price of 23.2982. This is -14.8% lower than average price of previous purchases of PCRX. |
| ARVN - Arvinas Inc | BUY | 100 @ USD 13.62 | USD 1,362 | The ETF bought 100 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 13.62 compared to the previous average buy price of 10.0517. This is 35.5% higher than average price of previous purchases of ARVN. |
| ABUS - Arbutus Biopharma Corp | BUY | 321 @ USD 4.16 | USD 1,335 | The ETF bought 321 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.16 compared to the previous average buy price of 3.90972. This is 6.4% higher than average price of previous purchases of ABUS. |
| PAHC - Phibro Animal Health Corporation | BUY | 33 @ USD 39.52 | USD 1,304 | The ETF bought 33 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 39.52 compared to the previous average buy price of 31.9736. This is 23.6% higher than average price of previous purchases of PAHC. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 253 @ USD 5.14 | USD 1,300 | The ETF bought 253 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 5.14 compared to the previous average buy price of 2.4762. This is 107.6% higher than average price of previous purchases of IRWD. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 86 @ USD 14.94 | USD 1,285 | The ETF bought 86 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 14.94 compared to the previous average buy price of 13.8095. This is 8.2% higher than average price of previous purchases of KALV. |
| KURA - Kura Oncology Inc | BUY | 147 @ USD 8.47 | USD 1,245 | The ETF bought 147 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 8.47 compared to the previous average buy price of 8.36067. This is 1.3% higher than average price of previous purchases of KURA. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 289 @ USD 4.28 | USD 1,237 | The ETF bought 289 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.28 compared to the previous average buy price of 4.33261. This is -1.2% lower than average price of previous purchases of PRME. |
| CGEM - Cullinan Oncology LLC | BUY | 100 @ USD 12.34 | USD 1,234 | The ETF bought 100 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 12.34 compared to the previous average buy price of 9.04852. This is 36.4% higher than average price of previous purchases of CGEM. |
| PACB - Pacific Biosciences of California | BUY | 470 @ USD 2.57 | USD 1,208 | The ETF bought 470 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.57 compared to the previous average buy price of 1.7214. This is 49.3% higher than average price of previous purchases of PACB. |
| RGNX - Regenxbio Inc | BUY | 86 @ USD 13.41 | USD 1,153 | The ETF bought 86 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.41 compared to the previous average buy price of 10.7472. This is 24.8% higher than average price of previous purchases of RGNX. |
| MGTX - MeiraGTx Holdings PLC | BUY | 135 @ USD 8.01 | USD 1,081 | The ETF bought 135 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.01 compared to the previous average buy price of 7.44849. This is 7.5% higher than average price of previous purchases of MGTX. |
| ZLAB - Zai Lab Ltd | BUY | 61 @ USD 17.05 | USD 1,040 | The ETF bought 61 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 17.05 compared to the previous average buy price of 30.5685. This is -44.2% lower than average price of previous purchases of ZLAB. |
| ALT - Altitude Group Plc | BUY | 162 @ USD 6.17999 | USD 1,001 | The ETF bought 162 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 6.17999 compared to the previous average buy price of 4.843. This is 27.6% higher than average price of previous purchases of ALT. |
| FULC - Fulcrum Therapeutics Inc | BUY | 84 @ USD 10.94 | USD 919 | The ETF bought 84 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 10.94 compared to the previous average buy price of 10.3. This is 6.2% higher than average price of previous purchases of FULC. |
| REPL - Replimune Group Inc | BUY | 121 @ USD 7.53 | USD 911 | The ETF bought 121 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 7.53 compared to the previous average buy price of 9.08859. This is -17.1% lower than average price of previous purchases of REPL. |
| LYEL - Lyell Immunopharma Inc | BUY | 36 @ USD 25.28 | USD 910 | The ETF bought 36 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 25.28 compared to the previous average buy price of 10.7268. This is 135.7% higher than average price of previous purchases of LYEL. |
| PRTA - Prothena Corporation plc | BUY | 91 @ USD 9.73 | USD 885 | The ETF bought 91 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 9.73 compared to the previous average buy price of 9.44681. This is 3.0% higher than average price of previous purchases of PRTA. |
| KROS - Keros Therapeutics Inc | BUY | 47 @ USD 18.3 | USD 860 | The ETF bought 47 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 18.3 compared to the previous average buy price of 15.9889. This is 14.5% higher than average price of previous purchases of KROS. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 226 @ USD 3.8 | USD 859 | The ETF bought 226 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.8 compared to the previous average buy price of 2.99006. This is 27.1% higher than average price of previous purchases of MRVI. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 95 @ USD 8.49001 | USD 807 | The ETF bought 95 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 8.49001 compared to the previous average buy price of 7.71116. This is 10.1% higher than average price of previous purchases of FDMT. |
| SIGA - SIGA Technologies Inc | BUY | 116 @ USD 6.82001 | USD 791 | The ETF bought 116 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.82001 compared to the previous average buy price of 6.6318. This is 2.8% higher than average price of previous purchases of SIGA. |
| GLPG - Galapagos NV ADR | BUY | 22 @ USD 34.64 | USD 762 | The ETF bought 22 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 34.64 compared to the previous average buy price of 29.9703. This is 15.6% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 22 @ USD 34.64 | USD 762 | The ETF bought 22 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 34.64 compared to the previous average buy price of 29.9703. This is 15.6% higher than average price of previous purchases of GLPG. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 91 @ USD 8.02 | USD 730 | The ETF bought 91 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 8.02 compared to the previous average buy price of 5.09268. This is 57.5% higher than average price of previous purchases of VNDA. |
| AVXL - Anavex Life Sciences Corp | BUY | 142 @ USD 5.05 | USD 717 | The ETF bought 142 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 5.05 compared to the previous average buy price of 7.83865. This is -35.6% lower than average price of previous purchases of AVXL. |
| ACRS - Aclaris Therapeutics Inc | BUY | 169 @ USD 3.87 | USD 654 | The ETF bought 169 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 3.87 compared to the previous average buy price of 3.03807. This is 27.4% higher than average price of previous purchases of ACRS. |
| TRDA - Entrada Therapeutics Inc | BUY | 59 @ USD 11 | USD 649 | The ETF bought 59 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 11 compared to the previous average buy price of 8.37113. This is 31.4% higher than average price of previous purchases of TRDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 177 @ USD 3.65001 | USD 646 | The ETF bought 177 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.65001 compared to the previous average buy price of 4.58959. This is -20.5% lower than average price of previous purchases of RCKT. |
| ACIU - AC Immune Ltd | BUY | 166 @ USD 3.54 | USD 588 | The ETF bought 166 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.54 compared to the previous average buy price of 2.64788. This is 33.7% higher than average price of previous purchases of ACIU. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 139 @ USD 4.07 | USD 566 | The ETF bought 139 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 4.07 compared to the previous average buy price of 3.27825. This is 24.2% higher than average price of previous purchases of AVIR. |
| ALLO - Allogene Therapeutics Inc | BUY | 362 @ USD 1.53 | USD 554 | The ETF bought 362 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.53 compared to the previous average buy price of 1.36533. This is 12.1% higher than average price of previous purchases of ALLO. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 78 @ USD 7.06999 | USD 551 | The ETF bought 78 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 7.06999 compared to the previous average buy price of 8.06383. This is -12.3% lower than average price of previous purchases of BCYC. |
| EOLS - Evolus Inc | BUY | 101 @ USD 4.95001 | USD 500 | The ETF bought 101 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 4.95001 compared to the previous average buy price of 8.38896. This is -41.0% lower than average price of previous purchases of EOLS. |
| CABA - Cabaletta Bio Inc | BUY | 150 @ USD 3.02 | USD 453 | The ETF bought 150 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 3.02 compared to the previous average buy price of 2.32763. This is 29.7% higher than average price of previous purchases of CABA. |
| AUTL - Autolus Therapeutics Ltd | BUY | 293 @ USD 1.42 | USD 416 | The ETF bought 293 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.42 compared to the previous average buy price of 1.73669. This is -18.2% lower than average price of previous purchases of AUTL. |
| OABI - OmniAb Inc. | BUY | 205 @ USD 1.96 | USD 402 | The ETF bought 205 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.96 compared to the previous average buy price of 1.89082. This is 3.7% higher than average price of previous purchases of OABI. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 47 @ USD 7.45998 | USD 351 | The ETF bought 47 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.45998 compared to the previous average buy price of 12.0934. This is -38.3% lower than average price of previous purchases of ARCT. |
| EDIT - Editas Medicine Inc | BUY | 159 @ USD 2.11 | USD 335 | The ETF bought 159 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.11 compared to the previous average buy price of 2.57417. This is -18.0% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 85 @ USD 3.94 | USD 335 | The ETF bought 85 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 3.94 compared to the previous average buy price of 3.9389. This is 0.0% higher than average price of previous purchases of VYGR. |
| HUMA - Humacyte Inc | BUY | 269 @ USD 1.03 | USD 277 | The ETF bought 269 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.03 compared to the previous average buy price of 1.93472. This is -46.8% lower than average price of previous purchases of HUMA. |
| CRBU - Caribou Biosciences Inc | BUY | 144 @ USD 1.55 | USD 223 | The ETF bought 144 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.55 compared to the previous average buy price of 1.65445. This is -6.3% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-27 this would crystalise an overall loss. |